Derivatives of <scp>MOPS</scp> : promising scaffolds for <scp>SARS</scp> coronaviruses Macro domain‐targeted inhibition
The severe acute respiratory syndrome coronavirus (SARS-CoV/CoV-2) genome encodes 16 non-structural proteins (nsps), which coordinate cell remodeling, virus replication and participate in viral evasion. Notably, nsp3 contains a protein module termed Macro domain, which carries IFN antagonist activity that interferes with host innate immunity response. This domain is able to bind and hydrolyze ADP-ribose derivatives. This activity is correlated to viral escape and thus makes Macro domains a valuable therapeutic target. In the present paper, we report a SARS-CoV Macro domain structure in complex with a MOPS molecule. Based on our structural data, molecular docking was performed on a set of MOPS analogs in the ADP-ribose binding pocket. We present an ELISA-based assay to select hits based on the inhibition of recombinant SARS-CoV/CoV-2 Macro domain-ADP-ribose complex formation. Among the tested analogs, MOPSO and CAPSO are the more efficient in inhibiting ADP-ribose-binding. Structural analysis of these molecules in the ADP-ribose pocket reveals potential interactions with amino acid residues involved in the coordination of ADP-ribose. Overall, these findings suggest that MOPSO and CAPSO bear potential to be used as a scaffold for the design of Macro domain-specific inhibitors.
Authors
- Nadia Rabah (ORCID: https://orcid.org/0000-0001-6689-0462)
- François Ferrón (ORCID: https://orcid.org/0000-0002-8351-4992)
- Bruno Canard (ORCID: https://orcid.org/0000-0003-4924-1991)
- Karine Alvarez (ORCID: https://orcid.org/0000-0002-6108-6966)
- Oney Ortega Granda (ORCID: https://orcid.org/0000-0002-4359-7981)
- Benjamin Morin (ORCID: https://orcid.org/0000-0001-6632-0320)
Institutions
- Centre National de la Recherche Scientifique (FR)
- Aix-Marseille Université (FR)
Publication Details
- Journal
- FEBS Journal
- Published
- 2025-03-11
- DOI
- https://doi.org/10.1111/febs.70039
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Agence Nationale de la Recherche
- European Synchrotron Radiation Facility
- French Infrastructure for Integrated Structural Biology